Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2444975 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL6633538 | 0.99 | CHRM3 (0.97) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4883203 | 0.87 | CHRM3 (0.78) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL16209859 | 0.87 | CHRM3 (0.78) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL6635823 | 0.86 | CHRM3 (1.00) | CHRM3CHRM2CHRM1 | |
| SCHEMBL27779420 | 0.86 | CHRM3 (0.76) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL15015222 | 0.86 | CHRM3 (0.76) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL15127537 | 0.86 | CHRM3 (0.76) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL27779338 | 0.85 | CHRM3 (0.74) | CHRM3CHRM2CHRM1KEAP1NFE2L2 | |
| SCHEMBL4894399 | 0.84 | CHRM3 (0.73) | CHRM3CHRM2CHRM1KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1290251-A | N-acyl cyclic amine derivatives | BANYU PHARMA CO LTD (JP) | 2001-04-04 | — | — | CN | claimed |
| US-8450362-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120277250-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-8242138-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110294851-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8017617-B2 | Amidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-02 | — | — | US | disclosed |
| CN-1290251-A | N-acyl cyclic amine derivatives | BANYU PHARMA CO LTD (JP) | 2001-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294851-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
| US-20090170870-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
| US-20120277250-A1 | AMIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.